Overview

  • Product name

    Anti-Ras (mutated G12 D) antibody
    See all Ras primary antibodies
  • Description

    Rabbit polyclonal to Ras (mutated G12 D)
  • Host species

    Rabbit
  • Specificity

    G12D mutant specific.
  • Tested applications

    Suitable for: WB, IHC-Pmore details
  • Species reactivity

    Reacts with: Human
    Predicted to work with: Mouse, Rat, Chicken, Guinea pig, Cow, Dog, Pig, Xenopus laevis, Zebrafish
  • Immunogen

    Synthetic peptide corresponding to Human Ras (N terminal) (mutated G12 D). (Carrier-protein conjugated).
    Database link: P01111

  • Positive control

    • Human colon cancer tissue; AsPC-1 whole cell extract; Ras (mutant G12D) transfected 293T whole cell extracts.

Properties

Applications

Our Abpromise guarantee covers the use of ab221163 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/500 - 1/10000. Predicted molecular weight: 21 kDa.
IHC-P 1/100 - 1/1000.

Target

  • Function

    Ras proteins bind GDP/GTP and possess intrinsic GTPase activity.
  • Involvement in disease

    Defects in HRAS are the cause of faciocutaneoskeletal syndrome (FCSS) [MIM:218040]. A rare condition characterized by prenatally increased growth, postnatal growth deficiency, mental retardation, distinctive facial appearance, cardiovascular abnormalities (typically pulmonic stenosis, hypertrophic cardiomyopathy and/or atrial tachycardia), tumor predisposition, skin and musculoskeletal abnormalities.
    Defects in HRAS are the cause of congenital myopathy with excess of muscle spindles (CMEMS) [MIM:218040]. CMEMS is a variant of Costello syndrome.
    Defects in HRAS may be a cause of susceptibility to Hurthle cell thyroid carcinoma (HCTC) [MIM:607464]. Hurthle cell thyroid carcinoma accounts for approximately 3% of all thyroid cancers. Although they are classified as variants of follicular neoplasms, they are more often multifocal and somewhat more aggressive and are less likely to take up iodine than are other follicular neoplasms.
    Note=Mutations which change positions 12, 13 or 61 activate the potential of HRAS to transform cultured cells and are implicated in a variety of human tumors.
    Defects in HRAS are a cause of susceptibility to bladder cancer (BLC) [MIM:109800]. A malignancy originating in tissues of the urinary bladder. It often presents with multiple tumors appearing at different times and at different sites in the bladder. Most bladder cancers are transitional cell carcinomas. They begin in cells that normally make up the inner lining of the bladder. Other types of bladder cancer include squamous cell carcinoma (cancer that begins in thin, flat cells) and adenocarcinoma (cancer that begins in cells that make and release mucus and other fluids). Bladder cancer is a complex disorder with both genetic and environmental influences.
    Note=Defects in HRAS are the cause of oral squamous cell carcinoma (OSCC).
  • Sequence similarities

    Belongs to the small GTPase superfamily. Ras family.
  • Post-translational
    modifications

    Palmitoylated by the ZDHHC9-GOLGA7 complex. A continuous cycle of de- and re-palmitoylation regulates rapid exchange between plasma membrane and Golgi.
    S-nitrosylated; critical for redox regulation. Important for stimulating guanine nucleotide exchange. No structural perturbation on nitrosylation.
  • Cellular localization

    Cell membrane. Golgi apparatus membrane. The active GTP-bound form is localized most strongly to membranes than the inactive GDP-bound form (By similarity). Shuttles between the plasma membrane and the Golgi apparatus.
  • Information by UniProt
  • Database links

  • Alternative names

    • C BAS/HAS antibody
    • C HA RAS1 antibody
    • C-BAS/HAS antibody
    • c-H-ras antibody
    • C-HA-RAS1 antibody
    • CTLO antibody
    • GTPase HRas antibody
    • GTPase KRas antibody
    • GTPase NRas antibody
    • H ras antibody
    • H RASIDX antibody
    • H-Ras-1 antibody
    • H-RASIDX antibody
    • Ha-Ras antibody
    • HAMSV antibody
    • HRAS antibody
    • HRAS1 antibody
    • K ras antibody
    • K RAS2A antibody
    • K RAS2B antibody
    • K RAS4A antibody
    • K RAS4B antibody
    • K-RAS antibody
    • KRAS antibody
    • KRAS1 antibody
    • KRAS2 antibody
    • N-RAS antibody
    • N-terminally processed antibody
    • NRAS antibody
    • NRAS1 antibody
    • p21ras antibody
    • RASH_HUMAN antibody
    • RASH1 antibody
    • RASK2 antibody
    • Transforming protein p21 antibody
    • v Ha ras Harvey rat sarcoma viral oncogene homolog antibody
    • v Ki ras2 Kirsten rat sarcoma viral oncogene homolog antibody
    • v ras neuroblastoma RAS viral oncogene homolog antibody
    see all

Images

  • All lanes : Anti-Ras (mutated G12 D) antibody (ab221163) at 1/5000 dilution

    Lane 1 : Non-transfected 293T whole cell extract
    Lane 2 : Ras wild type transfected 293T whole cell extract
    Lane 3 : Ras mutated G12D transfected 293T whole cell extract

    Lysates/proteins at 30 µg per lane.

    Secondary
    All lanes : HRP-conjugated anti-rabbit IgG antibody

    Predicted band size: 21 kDa



    12% SDS-PAGE.

  • Anti-Ras (mutated G12 D) antibody (ab221163) at 1/500 dilution + AsPC-1 whole cell extract at 30 µg

    Secondary
    HRP-conjugated anti-rabbit IgG antibody

    Predicted band size: 21 kDa



    12% SDS-PAGE.

  • Immunohistochemical analysis of paraffin-embedded human colon cancer tissue labeling Ras (mutated G12D) with ab221163 at 1/1000 dilution.

  • Immunohistochemical analysis of paraffin-embedded human colon cancer tissue labeling Ras (mutated G12D) with ab221163 at 1/1000 dilution.

References

This product has been referenced in:

  • Oka M  et al. KRAS G12D or G12V Mutation in Human Brain Arteriovenous Malformations. World Neurosurg N/A:N/A (2019). Read more (PubMed: 30902772) »
  • Zhao X  et al. A CRISPR-Cas13a system for efficient and specific therapeutic targeting of mutant KRAS for pancreatic cancer treatment. Cancer Lett 431:171-181 (2018). WB, IHC . Read more (PubMed: 29870774) »
See all 3 Publications for this product

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab221163.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Sign up